The disclosure discloses the forging process of a magnesium alloy wheel hub comprises the following steps: step 1, heating a magnesium alloy bar to 350-420° C. and keeping the temperature for 20 minutes; step 2, forging and forming the bar under a 6000-ton forging press, and controlling the forging process in sections. The forging process of the disclosure adopts sectional control, different forging process parameters are adopted in different forging stages, so that magnesium alloy bars can exert maximum forgeability in different deformation stages, make magnesium alloy deformation process more continuous, make forging process easier, obtain forged magnesium alloy wheel hub with excellent properties, and greatly improve forging process and processing efficiency.

The present disclosure relates to the technical field of biomedical materials, more particularly to a degradable magnesium alloy in-situ composite anastomotic staple and a preparation method thereof. The anastomotic staple, with a composite structure, is mainly composed of Mg—Zn—Nd magnesium alloy with high strength and good plasticity (internal part), and corrosion-resistant MgF.sub.2 (external part), and is formed by in-situ synthesis of MgF.sub.2 with the outer layer of Mg—Zn—Nd magnesium alloy anastomotic staple. The magnesium alloy composite anastomotic staple provided by the present disclosure has good plastic deformation ability and mechanical strength, a low degradation rate, and a high biosafety level, which can meet the in-vivo implantation requirements. In addition, it can gradually degrade in vivo after achieving the medical effects in vivo, avoiding a second operation for removal.

A method for preparing a shear-assisted extruded material from a powder billet is provided, the method comprising providing a billet of material in substantially powder form; applying both axial and rotational pressure to the material to deform at least some of the contacted material; and extruding the material to form an extruded material. A method for preparing shear-assisted extruded material is provided, the method comprising applying both axial and rotational pressure to stock material to form an extruded material at a rate between 2 and 13 m/min. A method for preparing shear-assisted extruded material is provided. The method comprises applying both axial and rotational pressure to stock material to form an extruded material; and aging the extruded material for less than 3 hours. A method for preparing shear-assisted extruded material is provided. The method comprises providing a stock material for shear-assisted extrusion; and applying both axial and rotational force to the stock material to form an extruded material, wherein the axial force does not decrease during the extrusion.

A heat treatment method for improving the mechanical property and the biofunctional stability of a magnesium alloy is provided, comprising: (1) fully annealing an original cold-drawn magnesium alloy AZ31; (2) polishing a surface of the magnesium alloy AZ31 from the step (1) by a waterproof abrasive paper; (3) heating the magnesium alloy AZ31 obtained from the step (2) to a temperature of 330° C. to 350° C. and keeping the temperature for 3 to 4 hours; and (4) cooling the magnesium alloy AZ31 obtained from the step (3) to room temperature. A method for manufacturing a small-peptide-coated biomaterial and an application of the small-peptide-coated biomaterial are further provided.

A heat treatment method for improving the mechanical property and the biofunctional stability of a magnesium alloy is provided, comprising: (1) fully annealing an original cold-drawn magnesium alloy AZ31; (2) polishing a surface of the magnesium alloy AZ31 from the step (1) by a waterproof abrasive paper; (3) heating the magnesium alloy AZ31 obtained from the step (2) to a temperature of 330° C. to 350° C. and keeping the temperature for 3 to 4 hours; and (4) cooling the magnesium alloy AZ31 obtained from the step (3) to room temperature. A method for manufacturing a small-peptide-coated biomaterial and an application of the small-peptide-coated biomaterial are further provided.

An Mg—Li alloy contains more than 10.50% by mass and not more than 16.00% by mass of Li, not less than 2.00% by mass and not more than 15.00% by mass of Al, not less than 0.03% by mass and less than 1.10% by mass of Mn, impurities, and the balance of Mg. The impurities contain Fe at a concentration of 15 ppm or less. The alloy may optionally contain M, which is at least one element selected from the group consisting Ca, Zn, Si, Y, and rare earth metal elements with atomic numbers of 57 to 71.

An Mg—Li alloy contains more than 10.50% by mass and not more than 16.00% by mass of Li, not less than 2.00% by mass and not more than 15.00% by mass of Al, not less than 0.03% by mass and less than 1.10% by mass of Mn, impurities, and the balance of Mg. The impurities contain Fe at a concentration of 15 ppm or less. The alloy may optionally contain M, which is at least one element selected from the group consisting Ca, Zn, Si, Y, and rare earth metal elements with atomic numbers of 57 to 71.

Provided is an implant magnesium alloy having corrosion resistance, mechanical strength, ductility at the same time. In one aspect of the present invention, an implant magnesium alloy contains: x at % of Zn; a total of y at % of at least one element of Ca and Sr; and the balance of Mg and inevitable impurities. x and y satisfy formulae 1 and 2:

0.15≤x≤1.5  (Formula 1)

0.5≤y≤1.5.  (Formula 2)

Provided is an implant magnesium alloy having corrosion resistance, mechanical strength, ductility at the same time. In one aspect of the present invention, an implant magnesium alloy contains: x at % of Zn; a total of y at % of at least one element of Ca and Sr; and the balance of Mg and inevitable impurities. x and y satisfy formulae 1 and 2:

0.15≤x≤1.5  (Formula 1)

0.5≤y≤1.5.  (Formula 2)

A bioabsorbable implant including an elongated metallic element having more than 50% by weight a metal and being substantially free of rare earth elements, the elongated metallic element defining at least a portion of the bioabsorbable implant and including a wire formed into a discrete bioabsorbable expandable metal ring; at least two biostable ring elements, each biostable ring element having a biostable and radio-opaque metallic alloy, the bioabsorbable expandable metal ring being disposed adjacent to at least one of the biostable ring elements; at least one flexible longitudinal connector including a bioabsorbable polymer, the connector being disposed between at least two adjacent rings; and a coating having at least one pharmaceutically active agent disposed over at least a portion of one ring.